News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

September 2000

Is the Healthcare Workforce a Barrier to Cost Containment?

ByIsaac D. Montoya, PhD

September 1st 2000

Costs of Care for HIV Infection in a Managed Care Population from 1995 to 1997

ByDiane L. Lapins, MPH,Marta E. Urdaneta, PhD,James Barrett, MS,Elizabeth C. Hamel, BA,Phong T. Duong, PharmD,Leona E. Markson, ScD

September 1st 2000

Medicaid Managed Care Reimbursement for HIV and Its Implications for Access to Care

ByRichard Conviser, PhD,Miranda Murray, PhD,Denys Lau

September 1st 2000

Acquired Immunodeficiency Syndrome Wasting, Functional Performance, and Quality of Life

ByRonenn Roubenoff, MD, MHS

September 1st 2000

Management of High Blood Cholesterol Levels in Nova Scotian Adults: Comparison with the NCEP II and European Clinical Practice Guidelines

ByGeorge Kephart, PhD,Ingrid Sketris, PharmD,David MacLean, MD,Kadre Kass, MSc,Seema Nagpal, MSc

September 1st 2000

Educating Health Professionals: A Hepatitis C Educational Program in a Health Maintenance Organization

ByLucy Rose Fischer, PhD,Kathleen S. Conboy, RN, BSN,Dawn H. Tope, RN, MS,DeNae K. Shewmake

September 1st 2000

The Effect of Additional Shots on the Vaccine Administration Process: Results of a Time-Motion Study in 2 Settings

ByJames M. Pellisier, PhD,Paul M. Copland, MSPH, ScD,Lisa A. Jackson, MD, MPH,Joseph E. May, PE

September 1st 2000

Anti-inflammatory Therapy Reduces Total Costs of Asthma Care Compared with Bronchodilation: The Asthma Outcomes Registry

ByDaniel M. Huse, MA,Mason W. Russell, MAPE,Scott T. Weiss, MD, MS,Stuart C. Hartz, ScD

September 1st 2000

Trending on AJMC

COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD

Perceptions About CGMs Among Primary Care Physicians and Endocrinologists

Surrogate End Points, Drug Costs Complicate Oncology Formularies

Oncology Patients in Clinical Trials: A Health Care Cost Analysis

Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists